聖諾生物(688117.SH):2024年度淨利潤5473.63萬元,同比減少22.18%
格隆匯2月27日丨聖諾生物(688117.SH)公佈2024年度業績快報,2024年度公司實現營業收入45,534.33萬元,較上年同期增長4.67%;實現歸屬於母公司所有者的淨利潤5,473.63萬元,較上年同期減少22.18%;實現歸屬於母公司所有者的扣除非經常性損益的淨利潤4,994.72萬元,較上年同期減少17.04%。
報告期內,公司持續專注於主營業務多肽藥物CDMO、原料藥和製劑的協同發展,積極響應制劑集採政策的同時充分拓展原料藥境內外業務,使得公司營業收入維持穩定增長;但由於市場競爭日益激烈公司藥學研究業務收入較上期有所下降,導致淨利潤相應減少;爲提升公司產品的核心競爭力與產品的市場份額,公司不斷豐富產品研發管線,增加新產品的研發投入,同時擴大生產規模,加速產能建設,致使報告期內研發費用、財務費用支出呈增長趨勢,導致淨利潤髮生變化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.